Endocannabinoid System – How It Affects Your Entire Body

Imagine a biological system whose existence humanity didn't know about until 1988, yet it influences virtually every physiological process in the human body – from pain and mood to sleep, appetite, immune response, memory, reproduction, and brain development. This system truly exists. It's called the endocannabinoid system (ECS), and its discovery fundamentally changed our understanding of how the body maintains internal balance.

Cannapio seedsOur own brandBrowse ›Tip for this articleAuto Banana OG Kush - autoflowering seeds 5 pcs Cannapio€19.30Browse ›Tip for this articleAuto Pure Haze - 3pcs Cannapio Autoflowering Seeds€9.20Browse ›

Paradoxically, it was discovered through cannabis research: scientists investigating why THC affects the human brain stumbled upon an entire system of receptors and signaling molecules that evolution created long before humans ever learned to cultivate cannabis.

The Discovery of the Endocannabinoid System

Key Milestones

The ECS story begins in the 1960s, but its most important chapters came several decades later:

• 1964: Raphael Mechoulam and Yechiel Gaoni isolated delta-9-tetrahydrocannabinol (THC) as the primary psychoactive component of cannabis.
• 1988: Allyn Howlett and William Devane identified the first cannabinoid receptor – CB1 – in rat brain.
• 1992: Mechoulam and Devane discovered the first endogenous cannabinoid – anandamide (N-arachidonoylethanolamine, AEA). The name derives from the Sanskrit word ananda, meaning bliss.
• 1993: The second cannabinoid receptor – CB2 – was discovered, primarily in immune cells.
• 1995: Mechoulam identified the second major endocannabinoid – 2-arachidonoylglycerol (2-AG).
• 2004: Ethan Russo first formulated the hypothesis of Clinical Endocannabinoid Deficiency (CED).

This sequence of discoveries led to the definition of the ECS as a whole – a set of two receptors (CB1R and CB2R), two major endogenous ligands (anandamide and 2-AG), and enzymes responsible for their synthesis and degradation.

Components of the Endocannabinoid System

CB1 Receptors

CB1 receptors are the most abundant metabotropic receptors in the human brain. They are found predominantly in:

• Central nervous system – cerebral cortex, hippocampus (memory), basal ganglia (motor control), cerebellum (coordination), hypothalamus (appetite, thermoregulation).
• Peripheral tissues – liver, adipose tissue, muscle, gastrointestinal tract.

Functions of CB1 receptors:

CB1 receptors are the primary target of THC – their activation in the brain is responsible for cannabis's psychoactive effects: euphoria, altered perception, increased appetite, and motor slowdown.

CB2 Receptors

CB2 receptors are primarily associated with the immune system, though recent research finds them in other tissues as well:

• Immune cells – macrophages, B lymphocytes, T lymphocytes, NK cells, mast cells.
• Spleen and lymph nodes.
• Peripheral nervous system – microglia in the brain, Schwann cells.
• Bones – osteoblasts, osteoclasts.
• Skin – keratinocytes.
• Gastrointestinal tract.

Functions of CB2 receptors:

CB2 receptors play a key role in regulating immune and inflammatory responses. Their activation is generally associated with anti-inflammatory and immunomodulatory effects – making them an interesting therapeutic target for minor cannabinoids like CBG, which is a CB2 partial agonist.

Anandamide (AEA) – "The Molecule of Bliss"

Anandamide was the first discovered endocannabinoid. It has these key properties:

• Partial agonist of CB1 receptors – activates them but not to full extent (unlike THC).
• Weak agonist of CB2 receptors.
• Interacts with TRPV1 receptors (vanilloid receptor – pain and heat perception) and PPAR-gamma (metabolism regulation).
• Produced "on demand" – the body synthesizes it when needed and breaks it down immediately after.
• Degrading enzyme: FAAH (fatty acid amide hydrolase).

Physiological roles of anandamide:

• Mood and emotional state regulation – hence the nickname "molecule of bliss."
• Pain modulation – anandamide acts as an endogenous analgesic.
• Neuroprotection – neuron protection from excitotoxicity.
• Regulation of reproductive processes – proven role in embryo implantation.

Elevated anandamide levels have been measured after physical exercise. The phenomenon of "runner's high" – euphoria after intense exercise – is thus mediated primarily by anandamide, not exclusively by endorphins as previously assumed.

2-Arachidonoylglycerol (2-AG) – The Main Player

2-AG is quantitatively the dominant endocannabinoid in the human body: its brain concentrations are 2–3 orders of magnitude higher than anandamide.

• Full agonist of both CB1 and CB2 receptors – unlike anandamide, it activates both receptors fully.
• Key mediator of retrograde synaptic signaling – the postsynaptic neuron sends a return signal to the presynaptic neuron, thereby regulating transmission intensity.
• Degrading enzymes: MAGL (monoacylglycerol lipase), ABHD6, and ABHD12.

Physiological roles of 2-AG:

While anandamide is a gentle modulator with partial effect, 2-AG functions as "heavy artillery" – a full agonist in high concentration, responsible for the majority of retrograde signaling in the brain.

Enzymes: Synthesis and Degradation

The ECS operates as an "on-demand" system. Endocannabinoids are not stored in vesicles like serotonin or dopamine, but synthesized directly in the cell membrane at the moment of need.

Synthetic enzymes:
- NAPE-PLD – synthesizes anandamide from membrane phospholipids.
- DAGLalpha and DAGLbeta – synthesize 2-AG.

Degrading enzymes:
- FAAH – degrades anandamide. FAAH inhibition (for example via CBD) increases anandamide availability and prolongs its effect.
- MAGL – degrades approximately 85% of all brain 2-AG.

The "synthesis on demand – rapid degradation" mechanism enables extraordinarily precise local regulation: endocannabinoids act only where needed, and their effect is strictly time-limited.

How ECS Maintains Balance: Homeostasis

The ECS is by nature a homeostatic regulator – its primary function is to maintain the organism's internal balance. Whenever any physiological parameter deviates from optimal, the ECS activates and seeks to restore it to normal.

Examples of Homeostatic Regulation

The ECS doesn't work one-directionally – it neither stimulates nor inhibits broadly. It responds contextually: where there's excess, it dampens; where there's deficiency, it stimulates. This explains seemingly paradoxical cannabinoid effects – for example, CBD can be mildly stimulating at low doses while sedative at higher doses.

Extended View: "Endocannabinoidome"

Modern research shows that the ECS forms the core of a much larger signaling system that Italian biochemist Vincenzo Di Marzo called the endocannabinoidome. This expanded system includes:

• Additional receptors: TRPV1, TRPV2, TRPA1, GPR55, GPR18, GPR119, PPAR-alpha, PPAR-gamma, 5-HT1A.
• Additional lipid mediators: palmitoylethanolamide (PEA), oleoylethanolamide (OEA), N-arachidonoyldopamine (NADA).
• Additional enzymes: N-acylethanolamine acid amidase (NAAA) and others.

This expanded view explains why cannabinoids – whether endogenous or plant-derived – affect such a diverse spectrum of physiological processes. It's not just about two receptors, but an entire network of interconnected signaling pathways.

Clinical Endocannabinoid Deficiency (CED)

Russo's Hypothesis

In 2004, American neurologist and cannabinoid researcher Ethan Russo formulated the hypothesis of Clinical Endocannabinoid Deficiency (CED). In an updated article from 2016 in the journal Cannabis and Cannabinoid Research, he expanded and substantiated his theory with new evidence.

Russo postulated that insufficient endocannabinoid signaling – caused by low endocannabinoid production, reduced receptor density, or increased enzymatic degradation – may be the cause or contributing factor in a group of previously poorly explained disorders.

Russo's Triad

All three conditions share characteristic features:

• Pain sensitization (hyperalgesia).
• Occurrence in combinations (high comorbidity).
• Absence of clear organic finding on imaging.
• Inadequate response to conventional treatment.
• Anecdotal improvement after cannabinoid administration.

Current Evidence Status

Russo's hypothesis remains a hypothesis – it has neither been definitively proven nor refuted. But supportive data exists:

• In migraine patients, lower anandamide levels in cerebrospinal fluid have been measured.
• In fibromyalgia and IBS patients, changes in CB1 receptor expression have been noted.
• FAAH gene polymorphisms – encoding the enzyme responsible for anandamide degradation – are associated with increased risk of some psychiatric and pain conditions.

CED is a valuable concept because it offers potential explanation for a group of difficult-to-understand disorders and suggests that phytocannabinoids could help "supplement" what the body lacks in endocannabinoid signaling.

How Phytocannabinoids Interact with ECS

Phytocannabinoids – cannabinoids derived from the cannabis plant – interact with the ECS through various mechanisms. Contrary to simplified popular understanding, most of them don't work simply by "plugging into" CB1 or CB2 receptors like a key in a lock. The actual mechanism is considerably more complex.

THC (Delta-9-Tetrahydrocannabinol)

• Partial agonist of CB1 – mimics the effect of anandamide, but with significantly higher affinity and longer duration. This is what causes psychoactive effects.
• Partial agonist of CB2 – contributes to anti-inflammatory action.
• With regular THC use, the ECS becomes "overloaded": CB1 receptor downregulation occurs – reduction in their density and sensitivity – this is the basis of tolerance development.

CBD (Cannabidiol)

CBD interacts with the ECS much more subtly than THC:

• Does not bind directly to CB1 or CB2 receptors (any binding is minimal).
• Negative allosteric modulator of CB1 – changes receptor conformation so that THC binds with lower efficacy. This is the mechanism by which CBD dampens THC's psychoactive effects.
• FAAH inhibitor – slows anandamide degradation, thereby increasing its availability and prolonging action. This mechanism is considered one of the main sources of CBD's anxiolytic effect.
• 5-HT1A agonist (serotonin receptor) – contributes to antidepressant and anxiolytic effects.
• TRPV1 agonist – pain and inflammation modulation.
• PPAR-gamma agonist – metabolic effects.

This multi-target pharmacological profile explains why CBD exhibits such a broad spectrum of potential therapeutic effects: it doesn't work through one receptor but modulates the entire endocannabinoidome.

CBG (Cannabigerol)

• Partial agonist of CB2 with minimal CB1 activation – therefore doesn't produce psychoactive effects.
• Interacts with TRPV1, 5-HT1A and other receptors.
• Discussed in more detail in the article on minor cannabinoids CBG, CBN, THCV, and CBC.

Comparison of ECS Interactions

How to Support Your Own Endocannabinoid System

The ECS isn't influenced only by plant cannabinoids. There are numerous approaches to supporting its optimal function through daily habits.

Diet

• Omega-3 fatty acids – direct endocannabinoid precursors. Sources: fatty fish, walnuts, flax seeds, hemp seeds.
• Dark chocolate and cacao beans – contain anandamide-like compounds, inhibit FAAH, and are rich in flavonoids supporting ECS.
• Black pepper – contains beta-caryophyllene, a terpene with direct agonistic activity on CB2 receptors.

Movement

Aerobic exercise demonstrably increases anandamide and 2-AG levels in the blood. Post-exercise euphoria is mediated largely by endocannabinoids – not exclusively by endorphins as traditionally assumed.

Stress Management

Chronic stress reduces endocannabinoid tone, particularly anandamide levels. Regular meditation, yoga, or breathing exercises can help restore balance – and research suggests this effect is partly mediated by the ECS itself.

Sleep

The ECS is involved in circadian rhythm regulation. Quality and sufficient sleep supports healthy endocannabinoid signaling, while its chronic disruption damages it – creating a vicious cycle difficult to break.

Phytocannabinoids

CBD oil can support the ECS particularly through FAAH inhibition and increased anandamide levels. CBG oil works through direct CB2 receptor activation. Full spectrum products provide the entire spectrum of cannabinoids, terpenes, and flavonoids whose combination can lead to a synergistic – or "entourage" – effect.

ECS and the Future of Medicine

The endocannabinoid system is among the most intensively studied biological systems in modern biomedicine. Over 30,000 publications on PubMed document the dynamism of this research. The most significant directions include:

Targeted Medications

The pharmaceutical industry is developing compounds that selectively influence specific ECS components:

• FAAH inhibitors – increase anandamide availability without THC's psychoactive effects.
• MAGL inhibitors – increase 2-AG levels for analgesic and anti-inflammatory indications.
• Selective CB2 agonists – anti-inflammatory action without psychoactivity, a promising target for autoimmune diseases.

Personalized Medicine

Genetic polymorphisms of ECS enzymes (FAAH, MAGL) and receptors (CB1, CB2) significantly influence individual cannabinoid response. ECS pharmacogenomics could in the future enable precise treatment tailoring to the specific patient.

Diagnostics

Measuring endocannabinoid levels in blood or cerebrospinal fluid could serve as a biomarker for CED-related conditions – migraine, fibromyalgia, or IBS – and help identify patients who could most benefit from cannabinoid therapy.

Frequently Asked Questions (FAQ)

Does everyone have an endocannabinoid system?

Yes. The ECS is an evolutionarily ancient system present in all vertebrates – mammals, birds, reptiles, amphibians, and fish. It appears even in some invertebrates. In humans, the ECS develops prenatally and plays an indispensable role in nervous system development.

Can I have a "disorder" of the endocannabinoid system?

Theoretically yes – that's the essence of Russo's clinical endocannabinoid deficiency hypothesis. However, current diagnostic medicine doesn't yet have standardized tests for assessing ECS function in typical patients. Development of reliable biomarkers is among the research priorities.

Is THC "bad" and CBD "good" for ECS?

This assessment is oversimplified. Both substances are pharmacologically active with complex effects profiles. THC with occasional, low-dose use may support the ECS. With chronic, high-dose use, it causes CB1 receptor downregulation (tolerance) and can disrupt natural endocannabinoid signaling. CBD generally has a modulatory and supportive effect on ECS without tolerance risk. More in the article on cannabis microdosing.

How quickly does ECS recover after stopping cannabis use?

Imaging studies show that downregulated CB1 receptors in chronic THC users begin recovering within 2 days of abstinence and reach approximately normal values after 4 weeks. This process is called a "tolerance break" or "T-break" in practice.

Can the endocannabinoid system be "exhausted"?

The ECS cannot be exhausted in an irreversible sense. However, dysregulation can occur – temporarily reduced or excessive activity. Chronic stress, sleep deprivation, poor diet, and excessive exogenous cannabinoid use can temporarily shift the ECS from balance, and recovery to physiological baseline may take weeks.

Does age affect the endocannabinoid system?

Yes. With advancing age, CB1 receptor density decreases in some brain areas and baseline endocannabinoid levels change. These changes may contribute to age-related cognitive decline, increased pain sensitivity, and mood changes – and are the subject of growing gerontological research interest.

Conclusion

The endocannabinoid system is one of the most significant and complex regulatory systems in the human body. Its discovery – paradoxically inspired by cannabis research – opened an entirely new chapter in understanding how the organism maintains internal balance.

For anyone considering using CBD and other cannabinoid products, understanding the ECS is fundamental: cannabinoids don't work magically or unpredictably. They interact with a specific biological system through defined receptors, enzymes, and signaling pathways. This understanding will help you better navigate why choosing the right product, proper dosing, and a quality cannabinoid profile truly matter.

Sources

1. Review of the Endocannabinoid System. (2021). Biological and Pharmaceutical Bulletin. PMC
2. The Endocannabinoid System and its Modulation by Phytocannabinoids. (2015). Neurotherapeutics. PMC
3. Russo, E. B. (2016). Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis and Cannabinoid Research. PubMed
4. Endocannabinoid System: Chemical Characteristics and Biological Activity. (2023). Pharmaceuticals. MDPI
5. Harvard Health. The endocannabinoid system: Essential and mysterious. Harvard Health
6. Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses. (2021). PMC. PMC
7. Endocannabinoids and related N-acylethanolamines: biological activities and metabolism. (2018). Inflammation and Regeneration. BMC
8. Exploring the Endocannabinoid System: What Every Clinician Should Know. (2025). Cannabis Health News.